• Corpus ID: 8231925

Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability.

@article{Klicek2013StableGP,
  title={Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability.},
  author={Robert Klicek and Danijela Kolenc and Jelena mentor {\vS}uran and Domagoj Drmic and Luka Br{\vc}i{\'c} and Gorana Aralica and Marko Sever and Jadranka Katan{\vc}i{\'c} Holjevac and Bo{\vz}o Radi{\'c} and Tatjana Paveli{\'c} Turudi{\'c} and Antonio Kokot and Leonardo Patrlj and Rudolf Ru{\vc}man and Sven Seiwerth and Predrag Sikiric},
  journal={Journal of physiology and pharmacology : an official journal of the Polish Physiological Society},
  year={2013},
  volume={64 5},
  pages={
          597-612
        }
}
  • R. KlicekD. Kolenc P. Sikiric
  • Published 1 October 2013
  • Medicine, Biology
  • Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
Stable gastric pentadecapeptide BPC 157 was suggested to link inflammatory bowel disease and multiple sclerosis, and thereby, shown to equally counteract the models of both of those diseases. [] Key Method For colitis, cysteamine (400 mg/kg intrarectally (1 ml/rat)) and colon-colon anastomosis (sacrifice at day 3, 5, 7, and 14) were used.

Stable Gastric Pentadecapeptide BPC 157 Heals Established Vesicovaginal Fistula and Counteracts Stone Formation in Rats

BPC 157 therapy’s beneficial effects resulted in healing and no stone formation, with µg- and ng-regimens, either given daily perorally in drinking water or intraperitoneally.

Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats

BPC 157 restores myotendinous junction in accordance with the healing of the transected muscle, tendon, and ligament in rats, and counteracts muscle atrophy that is regularly progressive and brings muscle presentation close to normal.

Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats

The functional rescue provided by BPC 157 after spinal cord injury implies that B PC 157 therapy can impact all stages of the secondary injury phase.

Bowel adhesion and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine in rats

BPC 157 therapy can be suited for the realization of the peritoneal defect healing with minimal or no adhesion formation and unlike diverse effect of the NO-agents, the BPC 157 application effect regularly combines decrease on the increased NO- and MDA- values and the beneficial outcome (less adhesion Formation).

Effects of Diclofenac, L-NAME, L-Arginine, and Pentadecapeptide BPC 157 on Gastrointestinal, Liver, and Brain Lesions, Failed Anastomosis, and Intestinal Adaptation Deterioration in 24 Hour-Short-Bowel Rats

Diclofenac combined with nitric oxide (NO) system blockade was used to resolve the increasing early risks following major massive small bowel resectioning surgery, suggesting therapy with BPC 157 and the Nitric oxide synthase (NOS substrate) L-arginine, is efficacious.

Učinak pentadekapeptida BPC 157 na cijeljenje rektovaginalnih fistula u štakora [The effect of pentadecapeptide BPC 157 on healing of rectovaginal fistulas in rats]

BPC 157 effects appear to be suited to induce a full healing of rectovaginal fistulas in rats, with both rectal and vaginal defects simultaneously ameliorated and eventually healed.

Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: New insights

BPC 157 is a fundamental treatment that quickly restores blood supply to the ischemically injured area and rapidly activates collaterals and involves the NO system.

Stable Gastric Pentadecapeptide BPC 157 and Wound Healing

The antiulcer peptide, stable gastric pentadecapeptide BPC 157 is reviewed, focusing on the particular skin wound therapy, incisional/excisional wound, deep burns, diabetic ulcers, and alkali burns, which may be generalized to the other tissues healing.
...

References

SHOWING 1-10 OF 85 REFERENCES

Gastric Pentadecapeptide BPC 157 and Short Bowel Syndrome in Rats

Rats treated with pentadecapeptide BPC 157 showed not different jejunal and ileal diameters, constant jejunum-to-ileum ratio, and increased anastomosis breaking strength, suggesting it could be helpful to cure short bowel syndrome.

Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system.

BPC 157 accelerated parenterally or perorally the healing of colonic and skin defect, leading to the suitable closure of the fistula, macro/microscopically, biomechanically, and functionally (larger water volume sustained without fistula leaking).

Salutary effect of gastric pentadecapeptide BPC 157 in two different stress urinary incontinence models in female rats

Pentadecapeptide BPC 157, applied parenterally or per-orally, appears to ameliorate the SUI in rat models, improving the otherwise detrimental course of healing after VD and TU, which may be analogous to human injury.

The stable gastric pentadecapeptide BPC 157, given locally, improves CO2 laser healing in mice.

Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract.

In rat esophagitis and failed function of both lower esophageal sphincter (LES) and pyloricSphincters (PS), BPC 157 increased pressure in both spHincters till normal and reduced esophAGitis, and may improve gastrointestinal tract therapy.

Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions.

Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat

BPC 157, at all investigated intervals, given locally or intraperitoneally, accelerated post-injury muscle healing and also helped to restore the full function.

Ibuprofen hepatic encephalopathy, hepatomegaly, gastric lesion and gastric pentadecapeptide BPC 157 in rats.

Therapy effect of antiulcer agents on new chronic cysteamine colon lesion in rat

...